AI Article Synopsis
Article Abstract
Background: Invasive meningococcal disease (IMD) is a life-threatening disease, primarily affecting infants and children. Argentina introduced routine meningococcal vaccination in infants and adolescents in 2017, with MenACWY vaccination targeting serogroups A, C, W, and Y (current National Immunization Program [cNIP]). Serogroup B, more prevalent since 2015, became predominant in children. The dynamic trends of IMD epidemiology and availability of a four-component meningococcal B vaccine (4CMenB) call for a reassessment of the best schedule to optimize IMD prevention. The objective was to model the public health impact of routine 4CMenB and/or MenACWY in infants and adolescents, using different vaccination strategies compared with the cNIP in Argentina.
Methods: A published dynamic transmission model adapted for Argentina evaluated six vaccination strategies versus the cNIP: infant 4CMenB alone (1), infant 4CMenB with adolescent MenACWY (2), adolescent MenACWY alone (3), infant 4CMenB & MenACWY (4), infant MenACWY alone (5), and infant 4CMenB & MenACWY with adolescent MenACWY (6).
Results: Strategies including adolescent MenACWY with infant 4CMenB (or 4CMenB plus MenACWY) vaccination had the largest impact on increasing IMD prevention i.e., up to 23 % higher than the cNIP after 25 years. Strategies including 4CMenB (1, 2, 4, 6) had the largest reduction of serogroup B IMD (impact is seen among children 0-4 years old) i.e., a 39 % decrease within the first five years of introducing 4CMenB. Strategies including adolescent MenACWY (cNIP, 2, 3 and 6) had the largest reduction of serogroup ACWY IMD, with near elimination after 30 years (impact seen in all ages, due to herd protection).
Conclusions: Adding routine infant 4CMenB (either to the complete cNIP or instead of infant MenACWY) could further reduce IMD cases, sequelae, and deaths in Argentina. In addition, maintaining the adolescent MenACWY program, with its herd immunity benefits, could achieve near elimination of serogroup ACWY IMD over 30 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2024.126589 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina.
Vaccine
December 2024
GSK, Emerging Markets, Santiago, Chile.
Background: Invasive meningococcal disease (IMD) is a life-threatening disease, primarily affecting infants and children. Argentina introduced routine meningococcal vaccination in infants and adolescents in 2017, with MenACWY vaccination targeting serogroups A, C, W, and Y (current National Immunization Program [cNIP]). Serogroup B, more prevalent since 2015, became predominant in children.
View Article and Find Full Text PDFTwo meningococcal serogroup B vaccines are licensed for use in the United States. In August 2024, the Food and Drug Administration (FDA) changed the label for the meningococcal serogroup B MenB-4C vaccine (Bexsero) from a 2-dose schedule (intervals of 0 and ≥1 month) to a 2-dose schedule (0 and 6 months) and added a 3-dose schedule (0, 1-2, and 6 months), based on new immunogenicity data. On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) voted to update its recommendations for the MenB-4C dosing interval and schedule to align with the new FDA label.
View Article and Find Full Text PDFWhole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction.
Vaccine
December 2024
Department of Pediatrics, Faculty of Medicine, Universidad de Chile, 8380453, Chile; Infectious Diseases Unit, Hospital de niños Dr. Luis Calvo Mackenna, 7500000, Chile. Electronic address:
Article Synopsis
- This study examined the genetic makeup of Neisseria meningitidis strains from Chilean children using whole-genome sequencing (WGS) to assess potential vaccine effectiveness.* -
- Out of 42 strains analyzed, the most common types were MenB and MenW, with findings indicating varying levels of predicted vaccine coverage using tools like gMATS and MenDeVAR.* -
- The results revealed significant genetic variability among Chilean strains compared to those in other countries, which limits the ability to predict vaccine coverage accurately with existing methods.*
Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review.
Hum Vaccin Immunother
December 2024
Interdisciplinary Department of Medicine, Hygiene Unit, University of Bari Aldo Moro, Bari, Italy.
Article Synopsis
- There are two vaccines available to prevent serogroup B meningococcal disease: 4CMenB, which is part of routine infant immunizations, and MenB-fHbp.
- Immunogenicity data indicates that while protective antibody levels initially rise after vaccination, they decline over time, with a booster dose helping to restore levels initially.
- Current evidence suggests that a booster for adolescents who were vaccinated in infancy may not provide long-lasting protection, and revaccination might be necessary instead.
Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.
Vaccine
October 2024
Disease Dynamics Unit, University of Cambridge, United Kingdom.
Article Synopsis
- - The UK is reassessing its meningococcal disease vaccination strategy due to the discontinuation of the Menitorix® vaccine, with the MenACWY vaccine being considered a key solution integrated into teenage immunizations, while infant vaccination remains important due to high incidence rates.
- - Two UK studies were analyzed to adjust age-specific meningococcal carriage data, utilizing a dynamic model to assess the effects of MenACWY vaccinations for teenagers and infants, also factoring in changes during COVID-19 lockdowns.
- - Projections suggest the teenage MenACWY vaccination will effectively reduce disease carriage to below 1% by 2025, while infant vaccination at 3 months is more effective in preventing cases than at 12 months
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!